Drug Profile
PDC APB
Alternative Names: HPT-721; PDC-APBLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator ElSohly Laboratories; University of Mississippi
- Developer Hapten Sciences
- Class Immunotherapies; Skin disorder therapies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Contact dermatitis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Contact-dermatitis(Prevention) in USA (IM, Injection)
- 27 Apr 2021 PDC APB is still in phase I trial for Contact dermatitis (Prevention) in USA (NCT04853823)
- 22 Apr 2021 Hapten Sciences plans a phase I trial for Contact dermatitis (Prevention) in July 2021(IM, Injection) (NCT04853823)